Llwytho...
The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Hypoxia is an important feature of most solid tumors, conferring resistance to radiation and many forms of chemotherapy. However, it is possible to exploit the presence of tumor hypoxia with hypoxia-activated prodrugs (HAPs), agents that in low oxygen conditions undergo bioreduction to yield cytotox...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Front Pharmacol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8091515/ https://ncbi.nlm.nih.gov/pubmed/33953675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.636892 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|